prikaz prve stranice dokumenta Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
  Download
PDF 2.18 MB
Scientific paper - Original scientific paper
Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
Clinical Medicine, 7 (2018), 9; 1-12. https://doi.org/10.3390/jcm7090287
Bojanić, Kristina; Bilić Čurčić, Ines; Kuna, Lucija; Kizivat, Tomislav; Smolić, Robert; Raguž Lučić, Nikola; Kralik, Kristina; Šerić, Vatroslav; Ivanac, Gordana; Tucak-Zorić, Sandra; Včev, Aleksandar; Smolić, Martina

Institutional repository: Repository UHC Osijek

Cite this document

Bojanić, K., Bilić Čurčić, I., Kuna, L., Kizivat, T., Smolić, R., Raguž Lučić, N. ... Smolić, M. (2018). Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy. Clinical Medicine, 7. (9), 1-12. doi: 10.3390/jcm7090287

Bojanić, Kristina, et al. "Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy." Clinical Medicine, vol. 7, no. 9, 2018, pp. 1-12. https://doi.org/10.3390/jcm7090287

Bojanić, Kristina, Ines Bilić Čurčić, Lucija Kuna, Tomislav Kizivat, Robert Smolić, Nikola Raguž Lučić, Kristina Kralik, et al. "Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy." Clinical Medicine 7, no. 9 (2018): 1-12. https://doi.org/10.3390/jcm7090287

Bojanić, K., et al. (2018) 'Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy', Clinical Medicine, 7(9), pp. 1-12. doi: 10.3390/jcm7090287

Bojanić K, Bilić Čurčić I, Kuna L, Kizivat T, Smolić R, Raguž Lučić N, and sur.. Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy. Clinical Medicine [Internet]. 2018 [cited 2024 November 25];7(9):1-12. doi: 10.3390/jcm7090287

K. Bojanić, et al., "Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy", Clinical Medicine, vol. 7, no. 9, pp. 1-12, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:239:315693. [Accessed: 25 November 2024]

Metadata
Title (english)Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
AuthorKristina Bojanić
MBZ: 272625
AuthorInes Bilić Čurčić
MBZ: 268184
AuthorLucija Kuna
MBZ: 353546
AuthorTomislav Kizivat
MBZ: 302955
AuthorRobert Smolić
MBZ: 292166
AuthorNikola Raguž Lučić
MBZ: 350405
AuthorKristina Kralik
AuthorVatroslav Šerić
MBZ: 193563
AuthorGordana Ivanac
MBZ: 277952
AuthorSandra Tucak-Zorić
MBZ: 320540
AuthorAleksandar Včev
MBZ: 141721
AuthorMartina Smolić
MBZ: 292155
Author's institution(Clinical hospital center Osijek)
Author's institutionJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Abstract (english)
AIM: To determine the levels of Wnt inhibitors in patients treated with aromatase inhibitors (AIs) prior to therapy and to investigate their association with bone mineral density (BMD) and lifestyle parameters. METHODS: 137 breast cancer patients were divided into a group treated with 1 mg of anastrozole and a group w/o anastrozole therapy. Serum concentrations of sclerostin and dickkopf1 (DKK1) were measured by ELISA. BMD was measured by dual-energy X-ray absorptiometry (DXA). Lifestyle factors were investigated by a self-reported questionnaire. RESULTS: Sclerostin was significantly higher in the AI-treated group (31.8 pmol/L vs. 24.1 pmol/L; p < 0.001), whereas DKK1 was significantly lower in the AI-treated group (24.3 pmol/L vs. 26.02 pmol/L; p < 0.001). Total hip and femoral neck BMD were significantly lower in the AI-treated group. CONCLUSION: AI treatment was associated with increased levels of sclerostin and decreased levels of DKK1.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleClinical Medicine
Numberingvol. 7, no. 9, pp. 1-12
p-ISSN1470-2118
e-ISSN1473-4893
DOIhttps://doi.org/10.3390/jcm7090287
URN:NBNurn:nbn:hr:239:315693
Publication2018
Document URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162798/
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2019-11-11 14:01:26